Literature DB >> 19433709

Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response.

Geetanjali Davuluri1, Virginia Espina, Emanuel F Petricoin, Mark Ross, Jianghong Deng, Lance A Liotta, Bert M Glaser.   

Abstract

OBJECTIVE: To examine whether phosphorylated vascular endothelial growth factor (VEGF) receptors shed into the vitreous reflect the ongoing retinal and choroidal signal pathway activity in wet age-related macular degeneration (AMD).
METHODS: Vitreous samples obtained immediately prior to anti-VEGF injection from 11 patients with choroidal neovascularization were analyzed using reverse-phase microarrays. Two patients had samples collected at the time of injection and 1 month later. Samples from 5 patients were collected prior to vitrectomy for macular hole, epiretinal membrane, or retinal detachment.
RESULTS: Phosphorylated forms of VEGF receptor (VEGFR Y996 and Y1175), platelet-derived growth factor receptor beta (PDGFRbeta Y716 and Y751), and c-KIT (Y703) were present in the vitreous. A significant difference in PDGFRbeta Y751 (P < .002), VEGFR Y996 (P < .04), and VEGFR Y1175 (P < .006), but not c-KIT Y703 (P < .05) or PDGFRbeta Y716 (P < .96), was noted for the responders to treatment (n = 5) compared with nonresponders (n = 6) and controls (n = 5).
CONCLUSIONS: Vitreous levels of activated receptors constitute a new class of biomarkers. Activated forms of VEGF and PDGF receptors, previously not known to exist in the vitreous, correlate with response to anti-VEGF therapy. These findings could provide the basis for the development of individualized treatment and discovery of new therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19433709      PMCID: PMC3777775          DOI: 10.1001/archophthalmol.2009.88

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  31 in total

Review 1.  Protein microarrays: meeting analytical challenges for clinical applications.

Authors:  Lance A Liotta; Virginia Espina; Arpita I Mehta; Valerie Calvert; Kevin Rosenblatt; David Geho; Peter J Munson; Lynn Young; Julia Wulfkuhle; Emanuel F Petricoin
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

2.  Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases.

Authors:  Shinji Yoneda; Hideaki Hara; Akira Hirata; Mikiko Fukushima; Yasuya Inomata; Hidenobu Tanihara
Journal:  Jpn J Ophthalmol       Date:  2005 Mar-Apr       Impact factor: 2.447

3.  Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing.

Authors:  Sophie J Bakri; Melissa R Snyder; Jose S Pulido; Colin A McCannel; William T Weiss; Ravinder J Singh
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

4.  Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization.

Authors:  M Dougher; B I Terman
Journal:  Oncogene       Date:  1999-02-25       Impact factor: 9.867

Review 5.  Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.

Authors:  Katherine M Sheehan; Valerie S Calvert; Elaine W Kay; Yiling Lu; David Fishman; Virginia Espina; Joy Aquino; Runa Speer; Robyn Araujo; Gordon B Mills; Lance A Liotta; Emanuel F Petricoin; Julia D Wulfkuhle
Journal:  Mol Cell Proteomics       Date:  2005-01-25       Impact factor: 5.911

Review 6.  Age-related macular degeneration--emerging pathogenetic and therapeutic concepts.

Authors:  Karen M Gehrs; Don H Anderson; Lincoln V Johnson; Gregory S Hageman
Journal:  Ann Med       Date:  2006       Impact factor: 4.709

7.  Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy.

Authors:  Eisuke Ishizaki; Shinji Takai; Mari Ueki; Takatoshi Maeno; Midori Maruichi; Tetsuya Sugiyama; Hidehiro Oku; Tsunehiko Ikeda; Mizuo Miyazaki
Journal:  Am J Ophthalmol       Date:  2006-01       Impact factor: 5.258

Review 8.  Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.

Authors:  A L Takeda; J Colquitt; A J Clegg; J Jones
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

9.  Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies.

Authors:  Hans-Peter Gerber; Xiumin Wu; Lanlan Yu; Christian Wiesmann; Xiao Huan Liang; Chingwei V Lee; Germaine Fuh; Christine Olsson; Lisa Damico; David Xie; Y Gloria Meng; Johnny Gutierrez; Racquel Corpuz; Bing Li; Linda Hall; Linda Rangell; Ron Ferrando; Henry Lowman; Franklin Peale; Napoleone Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

10.  Junctional complexes in various epithelia.

Authors:  M G FARQUHAR; G E PALADE
Journal:  J Cell Biol       Date:  1963-05       Impact factor: 10.539

View more
  21 in total

Review 1.  Emerging therapeutic approaches in the management of retinal angiogenesis and edema.

Authors:  An Truong; Tien Y Wong; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2010-12-18       Impact factor: 4.599

Review 2.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

3.  Molecular biomarkers in glaucoma.

Authors:  Sanjoy K Bhattacharya; Richard K Lee; Franz H Grus
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-07       Impact factor: 4.799

4.  Translational vitreous proteomics.

Authors:  Vinit B Mahajan; Jessica M Skeie
Journal:  Proteomics Clin Appl       Date:  2013-11-04       Impact factor: 3.494

5.  Mass spectrometry-based characterization of the vitreous phosphoproteome.

Authors:  Davide Tamburro; Francesco Facchiano; Emanuel F Petricoin; Lance A Liotta; Weidong Zhou
Journal:  Proteomics Clin Appl       Date:  2010-10-04       Impact factor: 3.494

Review 6.  Reverse phase protein arrays: mapping the path towards personalized medicine.

Authors:  Rosa I Gallagher; Virginia Espina
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

Review 7.  Clinical pharmacology of intravitreal anti-VEGF drugs.

Authors:  Stefano Fogli; Marzia Del Re; Eleonora Rofi; Chiara Posarelli; Michele Figus; Romano Danesi
Journal:  Eye (Lond)       Date:  2018-02-05       Impact factor: 3.775

8.  Proteomic analysis of vitreous biopsy techniques.

Authors:  Jessica M Skeie; Eric N Brown; Harryl D Martinez; Stephen R Russell; Emily S Birkholz; James C Folk; H Culver Boldt; Karen M Gehrs; Edwin M Stone; Michael E Wright; Vinit B Mahajan
Journal:  Retina       Date:  2012 Nov-Dec       Impact factor: 4.256

9.  Protein Microarrays for Ocular Diseases.

Authors:  Guillermo Solís-Fernández; Ana Montero-Calle; Miren Alonso-Navarro; Miguel Ángel Fernandez-Torres; Victoria Eugenia Lledó; María Garranzo-Asensio; Rodrigo Barderas; Ana Guzman-Aranguez
Journal:  Methods Mol Biol       Date:  2021

10.  Aqueous cytokine and growth factor levels do not reliably reflect those levels found in the vitreous.

Authors:  Stephanie M Ecker; Joshua C Hines; Scott M Pfahler; Bert M Glaser
Journal:  Mol Vis       Date:  2011-11-09       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.